The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $5.64 in the prior trading day, Organogenesis Holdings Inc (NASDAQ: ORGO) closed at $5.16, down -8.52%. In other words, the price has decreased by -$8.52 from its previous closing price. On the day, 1.34 million shares were traded.
Ratios:
Our goal is to gain a better understanding of ORGO by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.80 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 156.41. For the most recent quarter (mrq), Quick Ratio is recorded 3.35 and its Current Ratio is at 3.69. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Lake Street on June 28, 2024, initiated with a Buy rating and assigned the stock a target price of $5.
On February 07, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $5.
On June 15, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $5.Morgan Stanley initiated its Equal-Weight rating on June 15, 2023, with a $5 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 04 ’25 when Driscoll Michael Joseph sold 25,000 shares for $5.10 per share. The transaction valued at 127,535 led to the insider holds 166,879 shares of the business.
Gillheeney Gary S. sold 55,615 shares of ORGO for $186,866 on Dec 13 ’24. The President and CEO now owns 3,044,779 shares after completing the transaction at $3.36 per share. On Dec 16 ’24, another insider, Gillheeney Gary S., who serves as the President and CEO of the company, sold 5,585 shares for $3.49 each. As a result, the insider received 19,492 and left with 3,039,194 shares of the company.
Valuation Measures:
As of this moment, Organogenesis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 920.54, and their Forward P/E ratio for the next fiscal year is 30.93. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.36 while its Price-to-Book (P/B) ratio in mrq is 2.47.
Stock Price History:
Over the past 52 weeks, ORGO has reached a high of $6.71, while it has fallen to a 52-week low of $2.16. The 50-Day Moving Average of the stock is 41.72%, while the 200-Day Moving Average is calculated to be 63.50%.
Shares Statistics:
A total of 125.73M shares are outstanding, with a floating share count of 64.38M. Insiders hold about 49.26% of the company’s shares, while institutions hold 49.46% stake in the company.
